Invasive Pneumococcal Disease Characterization in Adults and Subgroups aged < 60 years and ≥ 60 years in Bogota, Colombia
- PMID: 35774639
- PMCID: PMC9231666
- DOI: 10.1016/j.ijregi.2022.04.007
Invasive Pneumococcal Disease Characterization in Adults and Subgroups aged < 60 years and ≥ 60 years in Bogota, Colombia
Abstract
Background: There is scarce information on the burden of invasive pneumococcal disease (IPD) among adults in low- and middle-income countries. This study aimed to describe the clinical outcomes and microbiological characteristics associated with IPD in adults and subgroups aged 18-59 years and ≥60 years in Colombia.
Methods: A retrospective chart review study was conducted in five institutions of Bogotá from January 2011 to December 2017. Analyses were carried out for overall population and stratified by age group (18-59; ≥ 60 years).
Results: There were 169 IPD cases; median age was 58 years, 51.5% were male, and 80.5% had at least one comorbidity. Bacteremic pneumonia was the most common presentation (63.9%). The median length of hospital stay was 12 days with high healthcare resource utilization (HCRU): 58.6% required ICU and 53.3% inotropic support. Overall case-fatality rate (CFR) was 41.4%. Clinical outcomes were worse in patients ≥60 years old with significantly higher CFR and HCRU (ICU admission, mechanical ventilation, and inotropic support) compared to those aged 18-59 years. The most frequent serotypes were 3, 6 A/C, 14, and 19A. The sensitivity to penicillin in meningitis and non-meningitis isolates were 75% and 89.1% respectively.
Conclusions: IPD was associated with a substantial burden in adults and worse clinical outcomes and HCRU in older adults in Colombia. Surveillance data combined with clinical outcomes have the potential to inform age-based pneumococcal vaccination policies.
Keywords: Streptococcus pneumoniae, pneumococcal infection, adult, older adult, mortality; healthcare resource utilization, antimicrobial resistance.
© 2022 Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc.,, The Author(s).
Figures
References
-
- Agudelo CI, Castañeda-Orjuela C, Brandileone MCC, Echániz-Aviles G, Almeida SCG, Carnalla-Barajas MN, Regueira M, Fossati S, Alarcón P, Araya P, et al. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study. Lancet Infect Dis. 2021;21(3):405–417. - PMC - PubMed
-
- Amin-Chowdhury Z, Groves N, Sheppard CL, Litt D, Fry NK, Andrews N, Ladhani SN. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes. Vaccine. 2021;39(14):1997–2004. - PubMed
-
- Ardito M, Salmeron A, de Wouters L, Gordovil K, Vallejo M, Fossati S. Enfermedad neumococica invasiva en adultos posterior a la introduccion de la vacuna conjuagada al calendario nacional: serotipos y sensibilidad. [Invasive pneumococcal disease in adults after the introduccion of conjugated vaccine in the national program: serotypes and susceptibility] Rev del Hosp Priv Comunidad. 2016;19(1):5–7. https://www.hpc.org.ar/investigacion/revistas/volumen-19/enfermedad-neum... Spanish. [accessed 27 November 2021]
-
- Brandileone MC, Almeida SCG, Bokermann S, Minamisava R, Berezin EN, Harrison LH, Andrade AL. Dynamics of antimicrobial resistance of Streptococcus pneumoniae following PCV10 introduction in Brazil: Nationwide surveillance from 2007 to 2019. Vaccine. 2021;39(23):3207–3215. - PubMed
-
- Brandileone MC, Almeida SCG, Minamisava R, Andrade AL. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36(19):2559–2566. - PubMed
LinkOut - more resources
Full Text Sources
